Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
